Lv1
50 积分 2023-02-20 加入
Real‐world efficacy of single‐agent belantamab mafodotin in relapsed systemic AL amyloidosis
5小时前
已完结
Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma
5小时前
已完结
Belantamab mafodotin in Relapsed/Refractory AL Amyloidosis- real-world multi-center experience and review of the literature
5小时前
求助中
Pomalidomide-based maintenance post-autologous hematopoietic cell transplantation in multiple myeloma: a case series
1个月前
已完结
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
2个月前
已完结
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
2个月前
已完结
Clinical Challenges of Immune Checkpoint Inhibitors
2个月前
已完结
P-395 Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)
2个月前
已完结
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
2个月前
已完结
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
6个月前
已完结
皖公网安备34019202002308
